202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.[1][2][3]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
ReferencesEdit
- ^ Clinical trial number NCT04982068 for "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ^ Clinical trial number NCT04990544 for "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
- ^ "CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine". Coalition for Epidemic Preparedness Innovations. 21 July 2021. Retrieved 30 August 2021.
Scholia has a profile for 202-CoV (Q108541932). |